BioSpace News Archive

On June 23, Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product developed based on the company’s proprietary HIFI technology platform.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to BioNTech’s fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today announced that the Italian Medicines Agency, or Agenzia Italiana del Farmaco (AIFA), has authorized Alterity to conduct its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.

Select Medical Corporation and Inova Health System announced a joint venture to own and operate the first critical illness recovery hospital in Northern Virginia.

Oncopeptides AB announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use, has unanimously adopted a positive opinion recommending a full marketing authorization approval of Pepaxti® in EU.

Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.

Eliaz Therapeutics Inc, a therapeutic apheresis company, was awarded its second NIH grant, an SBIR phase 2 grant for $1.7M.

AMRA Medical will present the results of their recent study using magnetic resonance imaging (MRI) to measure muscle composition changes in individuals with metabolic disorders at the 2022 SCWD Conference.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.